Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ester doai
Patent
1997-03-10
1999-03-09
Killos, Paul J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Ester doai
A01N 3702
Patent
active
058801529
ABSTRACT:
This invention relates to butyrate prodrugs derived from lactic acid and pharmaceutical compositions and methods employing them, either alone or in combination with other agents, for increasing gamma globin and fetal hemoglobin in a patient. These compounds, compositions and methods are particularly effective in treating .beta.-hemoglobinopathies, including sickle cell syndromes and .beta.-thalassemia syndromes. This invention relates to the use of these prodrugs, alone or in combination with other agents, to stimulate cell differentiation which prevents proliferation of malignant cells. These methods are particularly useful in treating cancer, especially malignant hematological disorders. In addition, this invention relates to the use of these prodrugs in treating inflammatory bowel diseases.
REFERENCES:
patent: 3526518 (1970-09-01), Kleiman
patent: 4479957 (1984-10-01), Cullinan et al.
patent: 5196136 (1993-03-01), Dishart et al.
patent: 5454806 (1995-10-01), Shinonome
patent: 5569675 (1996-10-01), Rephaeli et al.
CA 118:116458 (1993).
CA 123:281728 (1995).
M. Bar-Zeev et al., "Laboratory Evaluation of Tick Repellents," J. Med. Ent., vol. 10, pp. 71-74 (1973).
Charles Chany and Italina Cerutti, "Antitumor Effect of ArginineButyrate in Conjunction with Corynebacterium Parvum and Interferon," Int. J. Cancer, vol. 30, pp. 489-493 (1982).
Zi-Xing Chen and Theodore R. Breitman, "Tributyrin: A Prodrug of Butyric Acid for Potential Clinical Application in Differentiation Therapy," Cancer Research, vol. 54, pp. 3494-3499 (1994).
Anne F. Collins et al., "Oral Sodium Phenybutyrate Therapy in Homozygous .beta.-Thalassemia: A Clinical Trial," Blood, vol. 85, pp. 43-49 (1995).
A. Hague et al., "Apoptosis in Colorectal Tumour Cells: Indiction by the Short Chain Fatty Acids Butyrate, Ppropionate and Acetate and the Bile Salt Deoxycholate," Int. J. Cancer, vol. 60, pp. 400-406 (1995).
Antonius A. Miller et al., "Clinical Pharmacology of Sodium Butyrate in Patients with Acute Leukemia," Eur. J. Clin. Oncol., vol. 23, No. 9, pp. 1283-1287 (1987).
Harold L. Newmark and Charles W. Young, "Butyrate and Phenacetate as Differentiating Agents: Practical Problems and Opportunities," J. Cell. Biochem., vol. 22, pp. 247-253 (1995).
Abraham Novogrodsky et al., "Effect of Polar Organic Compounds on Leukemic Cells: Butyrate-Induced Partial Remission of Acute Myelogenous Leukemia in a Child," Cancer, vol. 51, No. 1, pp. 9-14 (1983).
Abraham Nudelman et al., "Novel Anticancer Prodrugs of Butyric Acid," J. Med. Chem., vol. 35, pp. 694-704 (1992).
Kentaro Okumura et al., "Synthesis and Hypocholesterolemic Activities of Eritadenine Derivatives," J. Med. Chem., vol. 17, pp. 846-855 (1974).
Michiro Otaka et al., "Antibody-Mediated Targeting of Differentiation Inducers to Tumor Cells: Inhibition of Colonic Cancer Cell Growth In Vitro and In Vivo, A Preliminary Note," Biochem. Biophy. Res. Comm., vol. 158, No. 1, pp. 202-208 (1989).
Plilippe Pouillart et al., "Pharmokinetic Studies of N-Butyric Acid Mono- and Polyesters Derived form Monosaccharades," J. Pharm. Sci., vol. 81, No. 3, pp. 241-244 (1992).
K.N. Prasad, "Butyric Acid: A Small Fatty Acid with Diverse Biological functions," Life Sci., vol. 27, pp. 1351-1358 (1980).
Said Sebti et al., "A Convenient Conversion of 2-Acyloxy-3-chlorocarboxamides to 3-Acyloxy-2-azetidinones in Heterogeneous Media," Synthesis, vol. 7, pp. 546-549 (1983).
Showa, "Acyloxyacetic Acid Derivatives," CA 102:166,465, Abstract of JP 59190952 A2.
O.C. Velazquez et al., "Butyrate and the Colonocyte: Implications for Neoplasia," Dig. Dis. Sci., vol. 41, pp. 727-739 (1996).
Wurtz, Ann. Chim.(Paris), vol. 59, p. 177 (1860).
Li Bigin
Tung Roger D.
Haley, Jr. James F.
Killos Paul J.
Pierri Margaret A.
Vertex Pharmaceuticals Inc.
LandOfFree
Butyrate prodrugs derived from lactic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Butyrate prodrugs derived from lactic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Butyrate prodrugs derived from lactic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1321548